Handelsbanken Fonder Ab Invitae Corp Transaction History

Handelsbanken Fonder Ab

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	BUY	$1.71 - $3.61 $30,609 - $64,619	17,900 Added 57.19%	49,200 $92,000
Q4 2021 Feb 08, 2022	SELL	$14.7 - $28.67 $74,970 - $146,217	-5,100 Reduced 14.01%	31,300 $478,000
Q2 2021 Aug 03, 2021	BUY	$26.09 - $40.4 $148,713 - $230,280	5,700 Added 18.57%	36,400 $1.23 Million
Q1 2021 Apr 29, 2021	BUY	$33.06 - $56.93 $244,644 - $421,282	7,400 Added 31.76%	30,700 $1.17 Million
Q2 2020 Aug 13, 2020	BUY	$11.71 - $30.29 $272,843 - $705,757	23,300 New	23,300 $706,000
Q4 2019 Feb 14, 2020	SELL	$15.02 - $20.57 $4.73 Million - $6.48 Million	-315,000 Closed	0 $0
Q3 2019 Oct 31, 2019	SELL	$18.85 - $27.5 $377,000 - $550,000	-20,000 Reduced 5.97%	315,000 $6.07 Million
Q2 2019 Jul 12, 2019	BUY	$17.37 - $26.27 $5.82 Million - $8.8 Million	335,000 New	335,000 $7.87 Million

2.12M

Ticker NVTA
Exchange NYSE
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 235,266,000
Description
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and...

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

Stay updated on Handelsbanken Fonder Ab with notifications on news.